In vitro experiments demonstrated that treating human myeloma cell lines (HMCLs), such as XG-7, AMO-1, and JJN3, with HDACi significantly upregulated RASSF4 mRNA and protein levels, with particularly pronounced effects in cells exhibiting low baseline RASSF4 expression. Here, RASSF4 is linked to plasma cell myeloma.